November 24, 1993JAMA
Mortality Following Ventricular Arrhythmia Suppression by Encainide, Flecainide, and Moricizine After Myocardial Infarction
Why the study?
Does suppression of ventricular premature depolarizations with encainide, flecainide, or moricizine improve survival in patients with myocardial infarction and left ventricular dysfunction?
Population
3549 patients with myocardial infarction and left ventricular dysfunction
Comparison
Encainide, flecainide, or moricizine vs Corresponding placebo
Design
RCT, randomized, placebo-controlled, blinded therapy
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Antiarrhythmic suppression of VPBs increases mortality post-MI with LV dysfunction; challenges prior suppression hypothesis and contraindicates routine use.
Structured PICO
Does suppression of ventricular premature depolarizations with encainide, flecainide, or moricizine improve survival in patients with myocardial infarction and left ventricular dysfunction?
P
Population
3549 patients with myocardial infarction and left ventricular dysfunction
I
Intervention
Encainide, flecainide, or moricizine (long-term active antiarrhythmic drug therapy)
C
Comparator
Corresponding placebo
O
Outcome
Overall survival and survival free of cardiac arrest or arrhythmic deathhard clinical
The suppression of asymptomatic or mildly symptomatic ventricular arrhythmias with encainide, flecainide, or moricizine after myocardial infarction increases mortality and should not be performed.
Cite This Study
Andrew E. Epstein (1993) studied this question.